Uniqure NV
NASDAQ:QURE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.78
10.12
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Uniqure NV
Effect of Foreign Exchange Rates
Uniqure NV
Effect of Foreign Exchange Rates Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Effect of Foreign Exchange Rates | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Uniqure NV
NASDAQ:QURE
|
Effect of Foreign Exchange Rates
$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
||
Pharming Group NV
AEX:PHARM
|
Effect of Foreign Exchange Rates
$1.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
19%
|
||
ProQR Therapeutics NV
NASDAQ:PRQR
|
Effect of Foreign Exchange Rates
-€251k
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
argenx SE
XBRU:ARGX
|
Effect of Foreign Exchange Rates
$5.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
||
Merus NV
NASDAQ:MRUS
|
Effect of Foreign Exchange Rates
$3.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
LAVA Therapeutics NV
NASDAQ:LVTX
|
Effect of Foreign Exchange Rates
$1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
3.6m
USD
Based on the financial report for Sep 30, 2024, Uniqure NV's Effect of Foreign Exchange Rates amounts to 3.6m USD.
What is Uniqure NV's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 10Y
-3%
Over the last year, the Effect of Foreign Exchange Rates growth was -65%.